Lung cancer is the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) is the dominant type of this disease.1 Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK) that acts as the major driver of NSCLC; it regulates important tumorigenic processes, including proliferation, apoptosis, angiogenesis, invasion and drug resistance.2 EGFR is well known to localize to the plasma membrane, where it phosphorylates downstream substrates on their tyrosine residues in response to extracellular stimulation. This evidence concerns the gene EGFR and lung cancer.